The global opioid use disorder market size is expected to reach USD 4.5 billion by 2026, exhibiting a CAGR of 10.1% over the forecast period. The rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, the growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.
According to the CDC, around 130 Americans die every day due to opioid overdose and the U.S. government has designated this as a public health emergency. For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.
To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and the new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve the standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.
Opioid Use Disorder Market Report Highlights
On the basis of the drug, Buprenorphine was the largest revenue-generating segment in 2018. Its sublingual tablets and branded drug Suboxone are the most widely prescribed drug for OUD.
Suboxone is the most used medication in the OUD industry. Factors that can be linked to the high use of this drug are high effectiveness in the treatment of addiction, with limited risk for misuse & relatively minor adverse effects, and its beneficial formal coverage.
North America dominated the market in 2018 and is anticipated to maintain its dominance over the forecast period.
In February 2020, the Irish biopharmaceutical firm Alkermes announced that the US Food and Drug Administration (FDA) had cleared its VIVITROL. When the detoxification process is complete, the drug has been engineered to avoid relapse to opioid dependency.
“Would you Like/Try a Sample Report” Click the link below:https://www.grandviewresearch.com/industry-analysis/opioid-use-disorder-market/request/rs1
Opioid Use Disorder Market Segmentation
Grand View Research has segmented the opioid use disorder market on the basis of drug and region:
Opioid Use Disorder Drug Outlook (Revenue, USD Million, 2015 – 2026)
Buprenorphine
Bunavail
Sublocade
Suboxone
Zubsolv
Others
Methadone
Naltrexone
Opioid Use Disorder Regional Outlook (Revenue, USD Million, 2015 – 2026)
North America
The U.S.
Canada
Europe
The U.K.
Germany
France
Italy
Spain
Asia Pacific
Australia
China
Latin America and Middle East & Africa
Brazil
South Africa
Key Players in the Opioid Use Disorder Market
Indivior PLC
BioDelivery Sciences International, Inc.
Alkermes, Inc.
Orexo US, Inc.
Titan Pharmaceuticals, Inc.
Omeros Corporation
Camurus
Hikma Pharmaceuticals PLC
Have Any Query? Ask Our Experts for More Details on Report:https://www.grandviewresearch.com/inquiry/6201/ibb
Browse Related Report @
Opioids Market – https://www.grandviewresearch.com/industry-analysis/opioids-market
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research is a market research and consulting company that offers market research reports, syndicated and customized reports. The company is headquartered in San Francisco, California. It offers client engagement for business consulting and market intelligence from various domains. The clientele is based across various countries with queries coming from more than 50 industries worldwide. Grand View Research helps its clients to make informed decisions by helping them understand current trends and scenarios. Every year Grand View Research accomplishes more than 300 multi-country market studies to optimize consulting for clients.
Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.Email: Send EmailPhone: 1888202951Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United StatesCity: San FranciscoState: CaliforniaCountry: United StatesWebsite: https://www.grandviewresearch.com/industry-analysis/opioid-use-disorder-market